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Plasmodium Cysteine Repeat Modular Proteins
3 and 4 are essential for malaria parasite
transmission from the mosquito to the host
Bruno Douradinha1,6, Kevin D Augustijn2,5, Sally G Moore3, Jai Ramesar2, Maria M Mota1, Andrew P Waters4,
Chris J Janse2 and Joanne Thompson3*
Abstract
Background: The Plasmodium Cysteine Repeat Modular Proteins (PCRMP) are a family of four conserved proteins
of malaria parasites, that contain a number of motifs implicated in host-parasite interactions. Analysis of mutants of
the rodent parasite Plasmodium berghei lacking expression of PCRMP1 or 2 showed that these proteins are
essential for targeting of P. berghei sporozoites to the mosquito salivary gland and, hence, for transmission from
the mosquito to the mouse.
Methods: In this work, the role of the remaining PCRMP family members, PCRMP3 and 4, has been
investigated throughout the Plasmodium life cycle by generation and analysis of P. berghei gene deletion
mutants, Δpcrmp3 and Δpcrmp4. The role of PCRMP members during the transmission and hepatic stages of
the Plasmodium lifecycle has been evaluated by light- and electron microscopy and by analysis of liver stage
development in HEPG2 cells in vitro and by infecting mice with mutant sporozoites. In addition, mice were
immunized with live Δpcrmp3 and Δpcrmp4 sporozoites to evaluate their immunization potential as a
genetically-attenuated parasite-based vaccine.
Results: Disruption of pcrmp3 and pcrmp4 in P. berghei revealed that they are also essential for transmission of the
parasite through the mosquito vector, although acting in a distinct way to pbcrmp1 and 2. Mutants lacking
expression of PCRMP3 or PCRMP4 show normal blood stage development and oocyst formation in the mosquito
and develop into morphologically normal sporozoites, but these have a defect in egress from oocysts and do not
enter the salivary glands. Sporozoites extracted from oocysts perform gliding motility and invade and infect
hepatocytes but do not undergo further development and proliferation. Furthermore, the study shows that
immunization with Δcrmp3 and Δcrmp4 sporozoites does not confer protective immunity upon subsequent
challenge.
Conclusions: PCRMP3 and 4 play multiple roles during the Plasmodium life cycle; they are essential for the
establishment of sporozoite infection in the mosquito salivary gland, and subsequently for development in
hepatocytes. However, although Δpcrmp3 and Δpcrmp4 parasites are completely growth-impaired in the liver,
immunization with live sporozoites does not induce the protective immune responses that have been shown for
other genetically-attenuated parasites.
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Background
The malaria parasite, Plasmodium, is an obligate intra-
cellular parasite that must recognize, invade and
develop within a range of diverse cell-types during its’
complex lifecycle whilst evading host clearance
mechanism. A family of four conserved proteins, the
Plasmodium Cysteine Repeat Modular Proteins
(PCRMP1-4) that may be involved in several of these
processes has recently been described [1]. PCRMPs
contain motifs implicated in intercellular interactions
or host-protein binding, including Epidermal Growth
Factor (EGF-like) and Kringle domains, and a multi-
pass transmembrane domain that is characteristic of
integral membrane receptors or channels. Analyses
also revealed structural similarities with the ligand
binding domains of Tumor Necrosis Factor Receptor
(TNFR) superfamily members, suggesting that they
may bind host immune molecules and thereby modify
the course of the immune response.
It has previously been shown that PCRMP1 and 2
co-localize with the Plasmodium falciparum Erythro-
cyte Membrane Protein 1 (PfEMP1) within structures
(the Maurer’s Clefts) that traffic exported parasite pro-
teins to the surface of mature blood-stage parasites,
and that they are also expressed on the surface of
sporozoites. Pcrmp1 and 2 gene knockout parasites of
the rodent malaria model, Plasmodium berghei, estab-
lish normal blood-stage infection and transmit to the
mosquito to form oocysts that release large numbers
of sporozoites into the mosquito haemocoel. These
sporozoites are infectious to the mouse when injected
intravenously but are unable to target and invade mos-
quito salivary glands so do not transmit via infected
mosquito bite.
In this work, a similar transgenesis approach was
used to analyse the function of the remaining two
PCRMP family members, PCRMP3 and 4. The results
showed that they also play a role in sporozoite devel-
opment in the mosquito, although distinct from that of
PCRMP1 and 2, and an additional role in intrahepato-
cytic development. Very little is known of the molecu-
lar basis of sporozoite development within the liver
after they have invaded the hepatocytes [2] but the
proteins involved are under increasing scrutiny since
the discovery that Plasmodium sporozoites with speci-
fic genetic modifications (genetically-attenuated para-
sites; GAS or GAPs) may be as efficient as radiation-
attenuated sporozoites (RAS) in conferring protection
against Malaria [3-15]. Since sporozoites that do not
express PCRMP3 or 4 are fully growth-arrested in
hepatocytes, this study focused on the role of PCRMP3
and 4 in liver-stage parasite development and evalu-
ated the immunization potential of Δpcrmp3 and
Δpcrmp4 sporozoites.
Methods
Plasmodium berghei parasites and mice
The reference line of P. berghei ANKA strain used was
cl15cy1 [16]. Animal experiments in the Netherlands
were performed after a positive recommendation of
the Animal Experiments Committee of the LUMC
(ADEC) was issued to the licensee. The Animal Experi-
ment Committees are governed by section 18 of the
Experiments on Animals Act and are registered by the
Dutch Inspectorate for Health, Protection and Veterin-
ary Public Health, which is part of the Ministry of
Health, Welfare and Sport. The Dutch Experiments on
Animal Act is established under European guidelines
(EU directive no. 86/609/EEC regarding the Protection
of Animals used for Experimental and Other Scientific
Purposes).
Generation of Δpcrmp3 and Δpcrmp4 mutant parasites
Two different replacement constructs, pL1082
and pL1083 were made to disrupt pcrmp3 and
pcrmp4, respectively. Target regions of pcrmp3
(PBANKA_060670) and pcrmp4 (PBANKA_130080)
were amplified from genomic DNA of mixed blood
stages of P. berghei cl15cy1 using the following primers
(see Additional file 1, Table S1 for the sequence of the
primers): primers L1448 and L1449 for the 5’-target
region of pcrmp3; L1450 and L1451 for the 3’-target
region of pcrmp3); L1457 and L1458 for the 5’-target
region of pcrmp4; L1459 and L1461 for the 3’-target
region of pcrmp4. Fragments were digested (KpnI, Hin-
dIII and EcoRI, BamHI respectively) and ligated into
vector pB3D [17] that contains the Toxoplasma gondii
dihydrofolate reductase-thymidylate synthase (tgdhfr/ts)
selection cassette. For transfection, pL1082 and pL1083
were linearized with KpnI/BamHI and transfected into
purified schizonts of P. berghei. Transfection, selection
and cloning of mutant parasite lines was performed as
described [16] and were carried out in duplicate for
each gene, generating Δpcrmp3a and b and Δpcrmp4a
and b. Correct integration of the construct into the
genome of mutant parasites was analysed by Southern
blot analysis of digested genomic DNA and/or of FIGE
separated chromosomes [16]. Separated chromosomes
were hybridized with a DNA-probe specific for the
3’UTR region of pbdhfr/ts gene which recognizes the
integrated construct in the target locus on chromo-
some 6 (pcrmp3) or on chromosome 13 (pcrmp4) and
the endogeneous pbdhfr/ts gene on chromosome 7. In
addition, a probe specific for the selectable marker, the
tgdhfr/ts gene of the replacement constructs, was used.
For Southern analysis of digested DNA, DNA-probes
were used recognizing the 5’-regions of the pcrmp
genes, amplified using the primers L1448, L1449,
L1457 and L1458 (Additional file 1, Table S1).
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Determination of growth and multiplication of asexual
blood stages
The multiplication rate of asexual blood stages in vivo,
determined during the cloning procedure, is calculated
as follows: the percentage of infected erythrocytes in
Swiss OF1 mice (OF1-ico, Construct 242; age 6 weeks
old; Charles River) injected with a single parasite is
determined at day 8 to 11 by counting Giemsa stained
blood films. The mean asexual multiplication rate per
24 hour is then calculated assuming a total of 1.2 × 1010
erythrocytes per mouse [18,19]. The percentage of
infected erythrocytes in mice infected with reference
lines of the P. berghei ANKA strain consistently ranged
between 0.5 and 2% at day 8 after infection, resulting in
a mean multiplication rate of 10 per 24 h [18,19]. Such
an analysis is a sensitive method to quantify differences
in growth rate during the early phase of in vivo infec-
tions when the availability of suitable host cells (reticu-
locytes) is not a limiting factor [19].
Transmission electron microscopy
Guts from mosquitoes infected with WT, Δpcrmp3 and
Δpcrmp4 parasites were dissected as previously
described [20], and treated for Electron Microscopy
observation as reported in [21,22]. Samples were
observed in a TEM Jeol JEM - 100 CX II microscope.
Gliding and cellular assays for Δpcrmp3 and Δpcrmp4
sporozoites
WT and mutant sporozoites were obtained by dissection
of infected mosquitoes 17-25 days after the infectious
blood meal from salivary glands or guts respectively, as
previously described [20,23]. To assess sporozoite moti-
lity, circumsporozoite protein (CSP) gliding trails were
visualized by staining with a monoclonal antibody
against CSP [24,25]. The hepatoma cell line HepG2
(ATCC, HB8065), which is efficiently infected by P. ber-
ghei parasites and sustains their complete development,
was used for in vitro hepatocyte invasion assays [26].
Cells were maintained in DMEM supplemented with
10% Fetal Calf Serum and 1% Penicillin-Streptomycin
(complete DMEM), in an atmosphere containing 5%
CO2 and were periodically tested for mycoplasma infec-
tions, as previously described [27]. For migration and
infection assays, P. berghei sporozoites were added to
cell monolayers seeded 24 hours earlier on coverslips in
complete DMEM and used when confluence was ~80-
90%. Sporozoite migration through cells was quantified
by detection of parasite-wounded hepatocytes using a
cell-impermeant fluorescent tracer macromolecule, rho-
damin-dextran [24] and staining for CSP. Migration
through host cells was quantified as the percentage of
dextran-positive non-infected cells, and the number of
sporozoites that reach a final hepatocyte for infection
and further development, as the percentage of parasites
inside dextran-negative cells [24]. Intrahepatocytic devel-
opment was measured at 24, 48 and 56 hours after
infection, stained against parasite HSP70 [28] and with
the DNA dye diamidino-phenyl-indole (DAPI). Migra-
tion, infection and intrahepatocytic development was
imaged using Metamorph software (Molecular Devices,
Sunnyvale, California, USA). All assays were performed
at least twice and results were analysed by paired Ttest,
two tailed.
Immunizations
6-8 week old female BALB/c (H-2Kd) and C57BL6
(H-2Kb) were supplied by Haarlan, UK. Mice were
immunized intravenously with either Δpcrmp3 or
Δpcrmp4 sporozoites, according to regimens proven
effective for RAS and other GAPs; a single dose of
50,000 of mutant sporozoites for BALB/c and three
doses of 50,000/20,000/20,000 of mutant sporozoites for
C57BL6, weekly apart [7,8,29]. Immunized and naïve
control group mice were challenged 10 days later with
10,000 WT P. berghei sporozoites. Parasitaemia was
measured by blood smears and Giemsa staining from
day 4 onwards [7,8].
Results
PCRMP3 and 4 are expressed in blood and mosquito-
stage parasites
The P. berghei gene models of PCRMP3 and 4 are
PBANKA_060670 and PBANKA_130080 respectively.
PCRMP3 and 4 from P. berghei, Plasmodium vivax,
Plasmodium knowlesi and P. falciparum are shown in
alignment in Additional File 2. The open reading frame
(ORF) of the 5’ region of pbcrmp3 and 4, containing 2
and 1 introns respectively, was verified by RT-PCR of
cDNA prepared from blood infected with mixed asex-
ual-stage parasites and gametocytes. Peptides and
mRNA (expressed sequenced tags) from PfCRMP3
(PlasmoDB identifier; PFL0410w) and PfCRMP4
(PF14_0722) have been detected in P. falciparum blood-
stage parasites [30,31], and microarray data from Plas-
modium yoelli, P. falciparum and P. vivax (available at
PlasmoDB) are also consistent with a blood-stage pat-
tern of expression. In addition, peptides and mRNA of
PCRMP3 and 4 have been detected in P. berghei, P.
yoelli and P. falciparum mosquito midgut- and salivary
gland-sporozoites indicating that, like PCRMP1 and 2,
these family members may also play a role during
transmission.
Generation of P. berghei parasite lines with disrupted
pcrmp3 and pcrmp4 genes
To examine the role of PCRMP3 and PCRMP4 during
the Plasmodium life cycle, Δpcrmp3 and Δpcrmp4
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mutant parasite lines were generated. The genes were
disrupted using standard genetic modification technolo-
gies aimed at disruption of the gene via double cross-
over integration [16]. In these experiments, integration
of the construct deletes a fragment of 4965 bp or 3625
bp of the ORF of pbcrmp3 or pbcrmp4 respectively
encoding the Cysteine Repeat Modular and mTM
domains. After transfection, selected pyrimethamine-
resistant parasites were cloned for further genotype and
phenotype analysis. Correct integration of the constructs
in the cloned Δpcrmp3 and Δpcrmp4 parasites was
shown by Southern analysis of FIGE separated chromo-
somes and of digested genomic DNA (Figure 1). Trans-
fection, selection and cloning of mutant parasite lines
was carried out in duplicate for each gene. In each case,
growth and development of blood- and mosquito stage
parasites appeared the same in both mutant parasite
lines, and one of each was chosen for further analysis.
Δpcrmp3 and Δpcrmp4 parasites show normal blood
stage growth but defects in sporozoite release and
salivary gland invasion
The generation of mutants with a disrupted pcrmp3 or
pcrmp4 gene demonstrates that they are not essential
for survival of blood stage parasites. To determine if
pcrmp3 or pcrmp4 gene disruption has an effect on
parasite growth rate during blood stages, the in vivo
growth was analysed during the experiments in which
the mutant parasites were cloned by limiting dilution.
Such an analysis is a sensitive method to quantify differ-
ences in growth during the early phase of in vivo infec-
tions. In these experiments, no effect on the growth rate
of the mutant parasites was observed. All mice infected
with a single Δpcrmp3 or Δpcrmp4 parasite showed a
parasitaemia level of 0.5-2% at 8 days post infection;
therefore these mutant parasites have an asexual multi-
plication rate, similar to wildtype (WT) parasites, of 10
per 24 hours. Mutant parasites also produced gameto-
cytes that were infectious to Anopheles stephensi mos-
quitoes, and produced oocysts in comparable numbers
to WT parasites following transmission (WT, 176 ± 74
oocysts/infected mosquito; Δpcrmp3, 229 ± 83;
Δpcrmp4, 192 ± 106).
Plasmodium berghei sporogony occurs in an encapsu-
lated oocyst attached to the mosquito midgut epithelium.
A mature oocyst is a spherical cell, 30-40 μm in diameter,
limited by a plasma membrane and a thick capsule. It con-
tains numerous dividing nuclei and cytoplasmic mem-
branes that segregate into individual sporozoites from days
10-12 after an infective blood meal. In mosquitoes housed
at 18-19°C, sporozoites begin to exit oocysts from day 11-
12 and rapidly target and invade the salivary glands. At
day 21 of mosquito infection, salivary glands of mosqui-
toes infected with Δpcrmp3 or Δpcrmp4 parasites
contained no sporozoites whereas WT parasite-infected
mosquito salivary glands contained an average of 1742
sporozoites (n = 36). Many Δpcrmp3 or Δpcrmp4 sporo-
zoites were visible within oocysts at day 21 indicating a
reduced ability to egress (Figure 2.1). To determine
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Figure 1 Generation of Δpcrmp3 and Δpcrmp4 parasites. A.
Transfection of P. berghei parasites with constructs PL1082 or
PL1083 containing the tgdhfr gene flanked by target sequences for
homologous recombination within the pbcrmb3 or 4 loci generated
Δpcrmp3a and b and Δpcrmp4a and b respectively. Fragment sizes
produced by restriction enzyme digestion are shown in kb. X, Xho1;
K, Kpn1; H, HindIII; S, StuI; E, EcoR1, B, BamH1. B. Southern blots of
genomic DNA from WT and Δpcrmp3 or 4 clones digested with
enzymes indicated were hybridized with specific probes within the
5’ target region of pcrmp3 or 4. C. Chromosome analysis of Δpcrmp3
and 4 parasite clones. Chromosomes were hybridized to probes
specific for the P. berghei dhfr/ts 3’UTR region or for tgdhfr within
the selection cassette, as indicated. The pbdhfr/ts probe hybridizes
to the P. berghei dhfr/ts gene on chromosome 7. Both probes
hybridize to the site of integration of constructs PL1082 in the
pbcrmp3 locus on chromosome 6 in Δpcrmp3 or the site of
integration of PL1083 in the pbcrmp4 locus on chromosome 13 in
Δpcrmp4.
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whether mutant sporozoites are unable to egress due to
defective development, the morphology of sporozoite-con-
taining oocysts was analysed at two timepoints after infec-
tive blood meal by Electron Microscopy. At day 10, no
difference was observed between WT, Δpcrmp3 or
Δpcrmp4 oocysts; all contained numerous nuclei within
forming sporozoites (Figure 2.2) At day 18, WT oocysts
contained few nuclei and appeared degenerate or
undergoing melanization. In contrast, at day 18 the mem-
branes of mutant oocyst appeared intact and full of mor-
phologically-normal, segregated sporozoites.
Δpcrmp3 and Δpcrmp4 sporozoites show normal gliding
motility and hepatocyte traversal in vitro
Sporozoites undergo gliding motility, characterized by
circular movements across the substrate that propel the
1
2
Figure 2 Δpcrmp3 and Δpcrmp4 sporozoites develop normally but remain within mature oocysts. 1) At day 18 post infection, WT oocysts
(A) contain few sporozoites and show areas of degradation (arrowed), whilst sporozoites within Δpcrmp3 oocysts (B) are radially-aligned and are
retained within an intact cell wall. Scale = 100 mm. 2) WT (A), Δpcrmp3 (B) and Δpcrmp4 (C) oocysts are found in mosquito guts 10 days post
infection, developing between the mosquito epithelium (mo) and haemolymph (h). Several nuclei (n) in developing sporozoites are visible. No
morphological differences are observed. At day 18 post infection, WT oocysts contain few nuclei (D) whilst most Δpcrmp3 (E) and Δpcrmp4 (F)
mature oocysts are full of sporozoites (sp). Scale = 5 μm.
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parasite forward and leaves a trail of CSP [24,32,33].
Oocyst-derived Δpcrmp3 and Δpcrmp4 sporozoites
deposit several circular trails (3.7 ± 1.6 and 3.7 ± 1.5
respectively; n = 6) per sporozoite) and show comparable
levels of gliding motility to WT sporozoites (3.5 ± 1.5; n
= 8) of the same age extracted from infected salivary
glands. Following transmission, sporozoites migrate
through several hepatocytes before invading and estab-
lishing infection in a final hepatocyte; a feature depen-
dent on sporozoite gliding motility [24,32]. Sporozoites
migrate through hepatocytes by disrupting their mem-
brane, which is rapidly repaired, but enter the hepatocyte
in which they will develop with the formation of a parasi-
tophorous vacuole (PV). Cells that have been traversed
can be visualized using a rhodamine-dextran tracer that
enters the cell immediately after membrane disruption
and becomes trapped inside after its’ repair [24,32]. To
determine whether mutant parasites migrate through
hepatocytes, rhodamine dextran-positive, uninfected
hepatocytes that had been traversed by WT salivary
gland sporozoites and Δpcrmp3 and Δpcrmp4 sporozoites
extracted from oocysts at day 21 post infection were
quantified. The results show that traversal of either of the
mutant parasites through HepG2 cells does not differ sig-
nificantly (P < 0.05) from WT sporozoites (Figure 3.1).
Δpcrmp3 and Δpcrmp4 sporozoites have impaired
intrahepatocytic growth
Following infection of the hepatocyte, sporozoites develop
into exo-erythrocytic forms (EEFs), forming trophozoites,
schizonts and merozoites, which are released into the
bloodstream. To determine whether Δpcrmp3 and
Δpcrmp4 sporozoites develop within hepatocytes, WT sali-
vary gland sporozoites and mutant sporozoites extracted
from oocysts at day 21 post-infection were incubated with
HepG2 cells, and the number of EEFs was quantified (Fig-
ure 3.2). No significant differences were observed in the
level of infection. WT and mutant parasites formed similar
numbers of EEFs but Δpcrmp3 and Δpcrmp4 EEFs were
smaller and aberrant at 24 hours and did not undergo any
further growth or nuclear division (Figure 3.3). Mutant
EEFs persisted up to 56 hrs post invasion but infected
hepatocytes showed no nuclear condensation or fragmen-
tation or other morphological indications of apoptosis.
Δpcrmp3 and Δpcrmp4 sporozoites do not confer pro-
tective immunity to mice.
Immunization with sporozoites that are attenuated by
irradiation or genetic modification and that infect hepato-
cytes but arrest development at an early stage can confer
protection against subsequent challenge with infectious
sporozoites [3,5-15,34]. Since Δpcrmp3 and Δpcrmp4 para-
sites also arrest during development in hepatocyes, it was,
therefore, determined whether they can confer protection
in a similar way. Balb/c and C57BL/6 mice were
immunized intravenously with Δpcrmp3 or Δpcrmp4
sporozoites extracted from mature oocysts at day 21 post-
infection. No immunized mice developed patent blood-
stage infections. Upon challenge with WT sporozoites,
however, all immunized mice developed a blood-stage
parasitemia with similar pre-patent periods and parasitae-
mia levels as naïve mice control (Figure 4) and showed no
protective immunity (Table 1).
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Figure 3 Δpcrmp3 and Δpcrmp4 sporozoites migrate through
and infect HepG2 cells. 1) HepG2 cells were incubated with WT
salivary gland sporozoites or with Δpcrmp3 or Δpcrmp4 oocyst-
derived sporozoites in the presence of rhodamine dextran.
Migration rates are expressed as the percentage of uninfected
traversed (rhodamine dextran +ve) cells ± the standard deviation. 2)
HepG2 cells were incubated with WT salivary gland sporozoites or
with Δpcrmp3 or Δpcrmp4 oocyst-derived sporozoites and the
development of EEFs was quantified at 24 hours. Infected cells are
expressed as the mean ± the standard deviation for each coverslip.
3) WT parasites show normal development in EEFs at 24 hours post-
infection and develop into trophozites at 48 hours and schizonts at
56 hours. Δpcrmp3 and Δpcrmp4 parasites establish infection at 24
hours but remain small with irregular shapes. Fluorescence pictures
of EEF (green) and nuclei (blue). Scale = 5 μm.
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Discussion
This study demonstrated that the PCRMP family mem-
bers, PbCRMP3 and 4, play roles during parasite devel-
opment in the mosquito and in the liver of the
vertebrate host that are distinct from family members
PCRMP1 and 2. In the mosquito, both PCRMP3 and 4
are involved in the process of egress of morphologically
mature sporozoites from oocysts. Mutant sporozoites
lacking expression of these proteins are released ineffi-
ciently from oocysts and do not invade the mosquito
salivary gland, so are unable to transmit to the mamma-
lian host. This phenotype shows some similarity with
that of parasites containing mutations in the conserved
region II plus of Circumsporozoite Protein (CSP;
PBANKA_040320) and in parasite mutants lacking
expression of Egress Cysteine Protease 1 (ECP1;
PBANKA_030470), PSOP9 (PBANKA_070190) and
Sporozoite Invasion-associated Protein 1, (SIAP-1;
PBANKA_100620) [35-38]. However, unlike CSP,
PSOP9 and SIAP-1 mutants, Δpcrmp3 and Δpcrmp4
sporozoites developing within oocysts not only appear
normal at the ultrastructural level but are also able to
undergo gliding motility and hepatocyte invasion, sug-
gesting that the defect does not lie indirectly in incor-
rect assembly or maturation of components of the
motility machinery (such as CSP). In this respect, the
mutant phenotype observed most closely resembles that
of Δpcrmp1 and Δpcrmp2 parasites, although occurring
at an earlier stage of sporozoite development. Although
further experiments are required to determine the pre-
cise role of PCRMP3 and 4 in oocyst egress, it is intri-
guing that the small numbers of sporozoites that are
released from oocysts do not invade the salivary glands.
As with PCRMP1 and 2, this may indicate a defect in
targeting or initiation of motility in the physiological
environment of the midgut, and thus a possible role in
the signal transduction pathways that are known to
operate in all parasite stages undergoing migration.
Sporozoites of Δpcrmp3 and Δpcrmp4 extracted from
oocysts perform gliding motility in vitro and are able to
traverse through several hepatocytes before committing
to infection in a final hepatocyte with levels of infectivity
that are similar to those of WT sporozoites extracted
from salivary glands. It has previously been thought that
oocyst and haemolymph sporozoites are intrinsically less
infectious than those that reach the salivary gland, and
that infectivity is enhanced by mechanisms that are acti-
vated during salivary gland invasion [39,40]. Since it is
difficult to obtain sufficient numbers of mature WT
sporozoites from the haemolymph, however, these con-
clusions have largely arisen from experiments using
sporozoites extracted from oocysts at day 14 of develop-
ment. The results from this and a previous study [1]
have shown that mature sporozoites lacking expression
of PCRMPs extracted from oocysts and the haemolymph
at day 18-21 of development show levels of gliding
motility and hepatocyte infectivity that are comparable
to WT salivary gland sporozoites of the same age. These
observations, therefore, support an alternative view [41];
that the principal factors affecting sporozoite infectivity
in vitro are age and maturity, rather than a further
maturation process within the salivary gland. It should
be noted, however, that parasite transmission to a host
via mosquito bite is a more complex process requiring
sporozoite migration within the skin of the host at the
injection site [33,42,43] before entry into a blood vessel
and transport to the liver. Thus, further experiments are
needed to establish whether sporozoite maturation
within the Salivary Gland is important for infection in
vivo, and whether PCRMP3 and 4 play a role in this
process.
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Figure 4 C57BL/6 mice immunized with Δpcrmp3 (black
square) or Δpcrmp4 (black triangle) sporozoites develop a
patent infection with the same kinetics as unimmunized mice
(black diamond) upon subsequent infection with WT
sporozoites.
Table 1 Immunization with Δpcrmp3 or Δpcrmp4 sporozoites does not protect Balb/c or C57BL/6 mice against
subsequent challenge with WT sporozoites
Δpcrmp3 or Δpcrmp4 sporozoites WT #protected/# challenged
Mouse Strain Immunization Boost I Boost II Sporozoite Challenge Control Δpbcrmp3 Δpbcrmp4
Balb/c 50 000 - - 10 000 0/6 (0) 0/6 (0) 0/6 (0)
C57Bl/6 50 000 20 000 20 000 10 000 0/6 (0) 0/6 (0) 0/6 (0)
Groups of mice were immunized i.v. with 50,000 Δpcrmp3 or Δpcrmp4 sporozoites isolated from several mosquitoes. Boosts were performed with 20,000
sporozoites at weekly intervals. Mice were challenged with 10,000 WT sporozoites 10 days after immunization (Balb/c) or second boost (C57BL/6), and infections
were monitored by counting of giemsa-stained blood smears. All mice became positive on day 4 after challenge.
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These studies show that PCRMP3 and 4 play an addi-
tional role during parasite development within hepato-
cytes. Δpcrmp3 and Δpcrmp4 sporozoites traverse and
infect hepatocytes at WT rates but arrest development
at a very early stage and are unable to develop into the
replicating liver-stage forms. This phenotype differs
from that of parasites lacking expression of PCRMP1
and 2 that are not only able to initiate infection within
the liver but undergo further development and establish
blood-stage infection [1]. Immunization with genetically-
attenuated parasites that show a similar growth arrest in
the liver-stages may confer protection against subse-
quent infection with WT sporozoites, (reviewed in
[8,44]). However, immunization with Δpcrmp3 and
Δpcrmp4 sporozoites did not result in protective immu-
nity and challenge of immunized mice with wild type
parasites showed normal liver stage development as
determined by the length of the prepatent period. Inter-
estingly, it was observed that growth-arrested Δpcrmp3
and Δpcrmp4 parasites persist in infected hepatocytes
for prolonged periods but no evidence was found that
infected hepatocytes undergo apoptosis. Antigen presen-
tation is likely to be less efficient in the absence of
infected-hepatocyte apoptosis which provides a huge
array of antigens to antigen-presenting cells [45] and it
has been suggested that this mechanism plays an impor-
tant role in attenuated sporozoite-mediated protection
[5,7,8,46]. It is possible, therefore, that the lack of pro-
tection conferred by Δpcrmp3 and Δpcrmp4 sporozoites
is associated with the lack of induction of apoptosis.
Conclusions
In this work, the role of PCRMP3 and 4 was addressed
during different stages of the Plasmodium life cycle. The
results show that disruption of the respective genes led
to blocking of transmission of P. berghei parasites from
the mosquito, where they remain trapped inside oocysts,
to the mouse. The infectivity of Δpcrmp3 and Δpcrmp4
sporozoites to hepatocytes mirrors that or wild type
sporozoites derived from salivary glands. This observa-
tion implies that popular concept of “enhanced” infectiv-
ity of salivary gland sporozoites is more grounded in age
and maturity of the sporozoite rather than its activation
due to successful colonization of the salivary gland.
Δpcrmp3 and Δpcrmp4 sporozoites are also impaired in
maturing efficiently in the liver implying a further role
for these proteins during intrahepatocytic development.
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